Fibrinolytic Activity and the Effects of Beta-Pyridylcarbinol (Ronicol) in Patients with Arteriosclerosis Obliterans

1983 ◽  
Vol 50 (04) ◽  
pp. 797-799 ◽  
Author(s):  
L Grodzińska ◽  
M Basista ◽  
A Kȩdzior ◽  
R Korbut ◽  
E Kostka-Trąbka ◽  
...  
Keyword(s):  
Blood Flow ◽  
Clinical Improvement ◽  
Fibrinolytic Activity ◽  
Walking Distance ◽  
Term Therapy ◽  
Arteriosclerosis Obliterans ◽  
Platelet Aggregability ◽  
Long Term Therapy ◽  
Increased Blood Flow

SummaryTwenty-one patients with arteriosclerosis obliterans of lower extremities were treated with beta-pyridylcarbinol (Ronicol) for five weeks. The long-term therapy with beta-pyridylcarbinol did not influence platelet aggregability. Activation of the fibrinolytic system was observed. This fibrinolytic effect of Ronicol was abolished in patients treated with aspirin. In most cases a slight clinical improvement was seen, manifested by elongation of pain-free walking distance and increased blood flow in affected limbs. It is concluded that the therapeutic effect of Ronicol in humans may be partly mediated by the release of endogenous prostacyclin.

Long Term Therapy of Patients Suffering from Occlusive Arterial Diseases with Combined Therapy with Phenformin and Stanozolol

1975 ◽  
Author(s):  
M. Bielawiec ◽  
A. Perzanowshi ◽  
M. Myśliwiec
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Clinical Improvement ◽  
Platelet Function ◽  
Fibrinolytic Activity ◽  
Combined Therapy ◽  
Lower Limbs ◽  
Term Therapy ◽  
Long Term Therapy

Phenformin (Dibotin-Winthrop) 100 mg daily and Stanozolol (Stromba-Winthrop) 7,5 mg daily were given for at least half a year and longer periods to 75 patients suffering from coronary heart disease and obliterative arteriosclerosis of the lower limbs. Clinical improvement was observed in above 80% of the patients. Statisticaly significant increase of fibrinolytic activity and decrease of platelet function, fibrinogen, cholesterol, lipids, and beta-lipoproteins levels as well as platelet — leucocyte aggregates number in blood during the therapy were found. Readministration of phenformin and stanozolol after some time of cessation of the herapy caused the similar effects.The results of our investigations show that combined therapy with phenformin and stanozolol may be of value in prophylaxis and treatment of thrombotic conditions and occlusive arterial diseases.

scholarly journals Clinical Outcome of Pneumatic Dilatation in Patients with Achalasia Cardia: A Single-Center Prospective Study

2017 ◽  
Vol 08 (04) ◽  
pp. 182-186
Author(s):  
Amit Hanmant Shejal ◽  
Thazhath Mavali Ramachandran ◽  
Sunil Kumar N
Keyword(s):  
Clinical Improvement ◽  
Balloon Dilation ◽  
Pneumatic Dilatation ◽  
Term Therapy ◽  
Symptom Duration ◽  
Achalasia Cardia ◽  
Eckardt Score ◽  
Long Term Therapy

ABSTRACT Background and Aim: Pneumatic balloon dilation is one of the most commonly used and effective methods for treating patients with achalasia cardia. This study was performed to assess immediate and long-term response of pneumatic dilatation (PD) in these patients. Materials and Methods: Forty-four achalasia cardia patients, who underwent PD in our center from January 2013 to December 2015, were prospectively studied. Data from these patients were analyzed for clinical improvement in symptoms after dilatation procedure over this period as per Eckardt score. Patients who required repeated procedure and factors influencing remission of symptoms were analyzed. Results: A total of 44 patients underwent PD, among which three lost to follow up. Of the 41 patients, 21 were male (51.22%) and 20 were females (48.78%). Mean age was 38.68 (13–64) years. Median symptom duration before first dilatation was 18 months (2–240). Major symptoms at presentation were dysphagia (n = 41, 100%), regurgitation (n = 38 92.68%), chest pain (n = 31, 75.6%), and weight loss (n = 20, 48.78%). Mean follow-up period was 22.22 months (9–38). Forty (97.56%) patients had immediate clinical improvement after 1 dilatation, of which 38 (92.68%) patients did not require any further treatment. Mean Eckardt score was 6.82 (4–11) at the time of first dilatation which improved to 0.66 during follow-up. Two patients required second dilatation (one 5 months and other 18 months after the first procedure). Conclusion: PD is a safe and effective long-term therapy for achalasia cardia and has a good long-term clinical remission.

Antithrombotic Therapy for DVT/PE

1997 ◽  
Vol 17 (03) ◽  
pp. 161-162
Author(s):  
Thomas Hyers
Keyword(s):  
Molecular Weight ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Cost Effective ◽  
Therapeutic Agents ◽  
Great Promise ◽  
Term Therapy ◽  
Low Molecular Weight ◽  
Long Term Therapy

SummaryProblems with unfractionated heparin as an antithrombotic have led to the development of new therapeutic agents. Of these, low molecular weight heparin shows great promise and has led to out-patient therapy of DVT/PE in selected patients. Oral anticoagulants remain the choice for long-term therapy. More cost-effective ways to give oral anticoagulants are needed.

Office-based post-marketing surveillance study on the influence of long term therapy with aripiprazole in patients with schizophrenia

2007 ◽  
Vol 40 (05) ◽  
Author(s):  
M Kungel ◽  
A Engelhardt ◽  
T Spevakné-Göröcs ◽  
M Ebrecht ◽  
C Werner ◽  
...  
Keyword(s):  
Surveillance Study ◽  
Term Therapy ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Long Term Therapy

scholarly journals Amiodarone-induced thyroid dysfunction in children: insights from the THYRAMIO study

2021 ◽  
Vol 12 ◽  
pp. 204201882110011
Author(s):  
Sarah Montenez ◽  
Stéphane Moniotte ◽  
Annie Robert ◽  
Lieven Desmet ◽  
Philippe A. Lysy
Keyword(s):  
Predictive Value ◽  
Thyroid Dysfunction ◽  
Term Therapy ◽  
Older Children ◽  
Thyroid Status ◽  
Clinical Series ◽  
Amiodarone Treatment ◽  
Long Term Therapy ◽  
Treatment Dosage

Background: Amiodarone treatment is effective against various types of arrhythmias but is associated with adverse effects affecting, among other organs, thyroid function. Amiodarone-induced thyroid dysfunction was not thoroughly evaluated in children as it was in adults, yet this affection may lead to irreversible neurodevelopmental complications. Our study aimed to define the incidence and risk factors of amiodarone-induced thyroid dysfunction in children. Methods: The study was designed as an observational study with a retrospective clinical series of 152 children treated by amiodarone in the Pediatric Cardiology Unit of our center from 1990 to 2019. All patients were divided into three groups according to their thyroid status: euthyroid, AIH (amiodarone-induced hypothyroidism) or AIT (amiodarone-induced thyrotoxicosis). Patients from these three groups were compared in terms of key clinical and therapeutic features. Results: Amiodarone-induced thyroid dysfunction was present in 23% of patients. AIT (5.3%) was three times less common than AIH (17.7%), and its occurrence increased with older age ( p < 0.05), treatment dosage ( p < 0.05), treatment duration ( p < 0.05) and the number of loading doses administered ( p < 0.05). There were no distinctive clinical features between euthyroid and AIH groups. A multivariable prediction model of AIT was built, with a yield of 66.7% as positive predictive value and 96.7% as negative predictive value. Conclusion: We observed that one in five children developed amiodarone-induced thyroid dysfunction. Special attention is required for older children with a high dosage and long-term therapy and who received a large number of loading doses, since these children are at risk to develop AIT, which is more delicate to manage than AIH.

Sign in / Sign up

Export Citation Format

Share Document